Will the NHS Cover the Wegovy Pill? What GPs and Patients Need to Know

The UK's first oral GLP-1 weight loss tablet was approved just weeks ago and it's already reshaping conversations in primary care.

On 11 June 2026, the MHRA approved the Wegovy pill (oral semaglutide) for weight management in the UK making it the first GLP-1 receptor agonist tablet licensed for obesity treatment in this country. After years of injectable dominance from Wegovy, Mounjaro, and Ozempic, a daily pill is finally on the horizon. But for the millions of patients already asking their GP about it, the reality is more complicated.

Here's what GPs, practice managers, and primary care professionals need to know right now.

What Is the Wegovy Pill?

The Wegovy pill contains semaglutide the same active ingredient as the injectable Wegovy in a once daily oral tablet. It is taken at a starting dose of 1.5 mg, increasing through 4 mg and 9 mg stages up to 25 mg, with at least one month at each dose level.

Clinical trials (the OASIS 4 study) show average weight loss of approximately 16.6% over 64 weeks broadly comparable to the injectable version. For patients who are needle-averse or find weekly injections difficult to manage, the pill offers a meaningful alternative.

Can Patients Get It on the NHS?

Not yet and NHS access is unlikely before 2027 at the earliest.

MHRA approval and NHS availability are two separate processes. Before the Wegovy pill can be prescribed on the NHS in England, it must go through a NICE Technology Appraisal to assess cost-effectiveness. That review has not yet begun, and based on previous GLP-1 appraisal timelines, NHS commissioning is unlikely before 2027 or 2028.

When it does reach the NHS, access is expected to follow a similar pathway to the injectable Wegovy restricted initially to specialist tier 3 weight management services, not routine GP prescribing.

For now, the pill will be available through private prescription only, once commercial stock is confirmed. Novo Nordisk has indicated a UK commercial launch in the second half of 2026.

What About Injectable GLP-1s on the NHS?

While the pill waits for NICE, GPs are already navigating significant workload pressure around injectable GLP-1s.

Both Wegovy (semaglutide) and Mounjaro (tirzepatide) are now available through NHS specialist weight management services but with strict eligibility criteria:

• Wegovy (injectable): BMI of 35 or above, plus at least one weight-related comorbidity. BMI thresholds are reduced by 2.5 points for patients from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds.
• Mounjaro: Being rolled out in a phased approach for patients with highest clinical need, with eligibility criteria evolving through the 2026/27 GP contract.

NHS access is still heavily rationed. Waiting times for specialist weight management services range from 40 weeks to roughly three years depending on location, and over 2 million UK adults are currently paying privately a ratio of approximately 7 to 1 compared to NHS users.

Why This Matters for GPs Right Now

The Wegovy pill approval is already generating patient enquiries and that pressure falls on primary care.

Weight-loss drug prescribing has been added to QOF indicators for the 2026/27 GP contract, with £25m of ring-fenced funding attached. GPs are now expected to more consistently identify and support patients living with obesity, including recording BMI and guiding appropriate referrals. But with ICBs still setting up prescribing pathways at different rates across the country, many GPs are finding themselves managing patient expectations with limited local infrastructure to back them up.

The RCGP has previously called for 'sufficient resource and funding to account for the increased workload' that GLP-1 prescribing brings a concern that will only grow as the oral pill adds a new wave of patient interest.

Key Takeaways for Primary Care

• The Wegovy pill was MHRA-approved on 11 June 2026 the first oral GLP-1 for weight loss in the UK.
• NHS prescribing is not available and will require a separate NICE Technology Appraisal, likely taking until 2027-2028.
• Private access is expected in the second half of 2026, through regulated UK prescribers and online pharmacies.
• Injectable Wegovy and Mounjaro remain the current NHS options, subject to strict eligibility criteria and local ICB rollout progress.
• GPs should expect an increase in patient queries and prepare with clear signposting on eligibility and local pathways.

A Growing Demand on Primary Care

With over 3.3 million Britons saying they want to start a GLP-1 medication within the next year, and an estimated 3.4 million people in England potentially eligible for NHS weight loss medication, the pressure on GP services is only set to increase.

Locum GPs with experience in obesity management and chronic disease or simply the capacity to support surging patient demand have never been more in need across UK primary care.

Looking for locum GP roles in primary care? Browse current vacancies at work.healthcare  the UK job board dedicated to locum GP opportunities.

Comments are disabled